Cohort Studymoderate evidence
Persistent tissue hypoperfusion improves risk stratification beyond vasopressor dose in refractory septic shock: a secondary analysis of the ANDROMEDA-SHOCK-2 trial.
Intensive care medicine·July 15, 2026·PMID 42467247
Why it mattersIdentifying refractory septic shock remains challenging, and current definitions rely heavily on vasopressor dose. This study demonstrates that incorporating bedside and laboratory markers of tissue hypoperfusion identifies a subgroup with markedly higher mortality, potentially guiding more aggressive interventions or enrollment in targeted trials.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled